Market Access News | pharmaphorum

News

Blue Shield of California bypasses PBMs to slash Humira pric...

Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the price of Humira by up to 90%

News

FDA issues summary of grants, promotes rare disease research

The US Food and Drug Administration (FDA) has provided an ‘at-a-glance’ summary of the agency’s news.

News

J&J's 340B rebate scheme stymied by strong-arm HRSA letter

Johnson & Johnson's stand against 340B abuse and duplicate discounts came to a halt in the face of HRSA threats of termination.

News

Sanofi's Dupixent scores double COPD win in US, China

Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.

News

Roche's PNH drug PiaSky backed for NHS use by NICE

Roche's PiaSky has been recommended for use by the NHS in England and Wales for the rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH), becoming the first option for patients th

News

BMS ends decades-long drought in novel schizophrenia drugs

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal.

Blue Shield of California bypasses PBMs to slash Humira pric...

FDA issues summary of grants, promotes rare disease research

J&J's 340B rebate scheme stymied by strong-arm HRSA letter

Sanofi's Dupixent scores double COPD win in US, China

Roche's PNH drug PiaSky backed for NHS use by NICE

BMS ends decades-long drought in novel schizophrenia drugs

Amazon puts $100m into global health drive

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks